Weekly Report: Influenza Summary Update

2008-2009 Influenza Season Week 19 ending May 16, 2009

All data are preliminary and may change as more reports are received.
(Due to the response to the novel influenza A (H1N1) investigation, surveillance regions were changed from Census Divisions to Department of Health and Human Services (HHS) Regions.)

Synopsis:

During week 19 (May 10 - 16, 2009), influenza activity decreased in the United States, however there are still higher levels of influenza-like illness than is normal for this time of year.

• One thousand seventy-four (15.1%) specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive for influenza.
• The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.
• Two influenza-associated pediatric deaths were reported.
• The proportion of outpatient visits for influenza-like illness (ILI) was below the national baseline. One of the ten surveillance regions reported ILI above their region-specific baseline.
• Five states reported geographically widespread influenza activity, 13 states reported regional activity, the District of Columbia and 15 states reported local influenza activity; 16 states reported sporadic influenza activity, and one state reported no influenza activity.

National and Regional Summary of Select Surveillance Components

HHS Surveillance Regions*	Data for current week			Data cumulative for the season
	Out-patient ILI?/strong>	% positive for flu?/strong>	Number of jurisdictions reporting regional or widespread activity?/strong>	A (H1)	A (H3)	Novel A (H1N1)	A (could not be subyped)?/strong>	A(Unsub-typed)	B	Pediatric Deaths
Nation	Normal	15.1 %	18 of 51	7,413	1,812	2,649	400	11,687	9,969	61
Region I	Elevated	10.9 %	3 of 6	523	137	210	13	1,080	798	1
Region II	Normal	16.7 %	2 of 2	267	107	135	13	1,057	706	8
Region III	Normal	13.3 %	2 of 6	1,152	157	149	52	614	1,338	9
Region IV	Normal	10.1 %	4 of 8	800	76	68	31	1,620	1,152	6
Region V	Normal	18.2 %	1 of 6	1,600	160	1,444	105	478	1,271	9
Region VI	Normal	4.8 %	2 of 5	716	94	91	1	3,936	2,427	12
Region VII	Normal	13.0 %	0 of 4	490	44	89	122	445	525	0
Region VIII	Normal	8.4 %	0 of 6	465	196	68	45	1,397	484	5
Region IX	Normal	36.1 %	4 of 4	1,043	589	288	13	744	616	10
Region X	Normal	28.6 %	0 of 4	357	252	107	5	316	652	1

* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and Region X: AK, ID, OR, WA)
?Elevated means the % of visits for ILI is at or above the national or region-specific baseline
?National data are for current week; regional data are for the most recent three weeks
?Includes all 50 states and the District of Columbia
?>99% of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further
testing

U.S. Virologic Surveillance:

WHO and NREVSS collaborating laboratories located in all 50 states and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.

During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United States. On April 15 and 17, 2009, CDC confirmed that two cases of febrile respiratory illness occurring in children who reside in adjacent counties in southern California were caused by infection with a novel influenza A (H1N1) virus. As of May 22, 2009, 6,552 confirmed infections with novel influenza A (H1N1) virus have been identified by CDC and state and local public health departments. Reporting of novel influenza A (H1N1) viruses by U.S. WHO collaborating laboratories began during week 17. The results of tests performed during the current week are summarized in the table below.

	Week 19
No. of specimens tested	7,127
No. of positive specimens (%)	1,074 (15.1%)
Positive specimens by type/subtype
Influenza A	1,026 (95.5%)
A (H1)	66 (6.4%)
A (H3)	80 (7.8%)
A (unsubtyped)	101 (9.8%)
A (could not be subtyped)	37 (3.6%)
A (novel influenza H1N1)	742 (72.3%)
Influenza B	48 (4.5%)

During week 19, seasonal influenza A (H1), A (H3), and B viruses continue to co-circulate with novel influenza A (H1N1). Approximately 73% of all influenza viruses being reported to CDC are novel influenza A (H1N1) viruses.

The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS collaborating laboratories may be due in part to changes in testing practices by healthcare providers, triaging of specimens by public health laboratories, an increase in the number of specimens collected from outbreaks, and other factors.

View WHO-NREVSS Regional Bar Charts| View Chart Data | View Full Screen

Antigenic Characterization:

CDC has antigenically characterized 1,368 seasonal human influenza viruses [827 influenza A (H1), 140 influenza A (H3) and 401 influenza B viruses] collected by U.S. laboratories since October 1, 2008.

All 827 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 2008-09 influenza vaccine (A/Brisbane/59/2007). All 140 influenza A (H3N2) viruses are related to the A (H3N2) vaccine component (A/Brisbane/10/2007).

Influenza B viruses currently circulating can be divided into two distinct lineages represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses. Fifty-eight influenza B viruses tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 343 viruses belong to the B/Victoria lineage and are not related to the vaccine strain.

Data on antigenic characterization should be interpreted with caution given that antigenic characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference ferret antisera and results may not correlate with clinical protection against circulating viruses provided by influenza vaccination.

Annual influenza vaccination is expected to provide the best protection against those virus strains that are related to the vaccine strains, but limited to no protection may be expected when the vaccine and circulating virus strains are so different as to be from different lineages, as is seen with the two lineages of influenza B viruses. Antigenic characterization of novel influenza A (H1N1) viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with seasonal influenza vaccine.

Antiviral Resistance:

Since October 1, 2008, 893 seasonal influenza A (H1N1), 145 influenza A (H3N2), and 444 influenza B viruses have been tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir). Eight hundred seventy-six seasonal influenza A (H1N1) and 145 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine). One hundred twenty-eight novel influenza A (H1N1) viruses have been tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir). Ninety-six novel influenza A (H1N1) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine). The results of antiviral resistance testing performed on these viruses are summarized in the table below.

	Isolates tested (n)	Resistant Viruses, Number (%)		Isolates tested (n)	Resistant Viruses, Number (%)
		Oseltamivir	Zanamivir		Adamantanes
Seasonal Influenza A (H1N1)	893	888 (99.4%)	0 (0)	876	4 (0.5%)
Influenza A (H3N2)	145	0 (0)	0 (0)	145	145 (100%)
Influenza B	444	0 (0)	0 (0)	N/A*	N/A*
Novel Influenza A (H1N1)	128	0 (0)	0 (0)	96	96 (100%)

      ? ^{*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses.}

Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with confirmed, probable or suspected cases of novel influenza A (H1N1) virus infection who are hospitalized or who are at higher risk for seasonal influenza complications. The novel influenza A (H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications, amantadine and rimantadine. Additional information on antiviral recommendations for treatment and chemoprophylaxis of novel influenza A (H1N1) infection is available at http://www.cy118119.com/h1n1flu/recommendations.htm

In areas that continue to have seasonal influenza activity, especially those with circulation of oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human influenza A (H1N1) virus infection.

Pneumonia and Influenza (P&I) Mortality Surveillance

During week 19, 6.7% of all deaths reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is below to the epidemic threshold of 7.3% for week 19.

View Full Screen

Influenza-Associated Pediatric Mortality

Two influenza-associated pediatric deaths were reported to CDC during week 19 (Arizona); one was due to influenza A virus (rapid test positive) and one was due to influenza B virus infection. The deaths reported this week occurred between April 12 and April 25, 2009. Since September 28, 2008, CDC has received 61 reports of influenza-associated pediatric deaths that occurred during the current season.

Of the 31 children who had specimens collected for bacterial culture from normally sterile sites, 13 (41.9%) were positive; Staphylococcus aureus was identified in eight (61.5%) of the 13 children. Three of the S. aureus isolates were sensitive to methicillin and five were methicillin resistant. Twelve of the 13 children with bacterial coinfections were five years of age or older and 10 (76.9%) of the 13 children were 12 years of age or older. An increase in the number of influenza-associated pediatric deaths with bacterial coinfections was first recognized during the 2006-07 influenza season. In January 2008, interim testing and reporting recommendations were released regarding influenza and bacterial coinfections in children and are available at (http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268).

View Full Screen

Influenza-Associated Hospitalizations

Laboratory-confirmed influenza-associated hospitalizations are monitored in two population-based surveillance networks: the New Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).

During October 12, 2008 to May 2, 2009, the preliminary laboratory-confirmed influenza-associated hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. Because of case identification methods utilized in this study, there is a delay from the date of hospitalization to the date of report.

View Full Screen

During October 1, 2008 ?May 16, 2009, preliminary laboratory-confirmed influenza-associated hospitalization rates reported by the EIP for children aged 0-4 years and 5-17 years were 3.7 per 10,000 and 0.7 per 10,000, respectively. For adults aged 18-49 years, 50-64 years, and = 65 years, the rates were 0.4 per 10,000, 0.5 per 10,000, and 1.5 per 10,000, respectively.

View Full Screen

Outpatient Illness Surveillance:

Nationwide during week 19, 1.7% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.4%.

View ILINet Regional Charts | View Chart Data |View Full Screen

On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 2.8%. One of the ten surveillance regions reported an ILI percentage above their region specific baseline. ILI decreased during week 19 in 8 of 10 regions compared to week 18. In regions 1 and 2, following a decrease in the percentage of visits for ILI during week 18, ILI increased during week 19.

Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of influenza activity.

During week 19, the following influenza activity was reported:

• Widespread influenza activity was reported by five states (Arizona, California, New Jersey, Texas, and Virginia).
• Regional influenza activity was reported by 13 states (Alabama, Connecticut, Georgia, Hawaii, Illinois, Massachusetts, Nevada, New Hampshire, New Mexico, New York, Pennsylvania, South Carolina, and Tennessee).
• Local influenza activity was reported by the District of Columbia and 15 states (Alaska, Colorado, Florida, Kansas, Louisiana, Maine, Maryland, Michigan, North Carolina, Oklahoma, Oregon, Rhode Island, Utah, Washington, and Wisconsin).
• Sporadic activity was reported by 16 states (Arkansas, Delaware, Idaho, Indiana, Iowa, Kentucky, Minnesota, Mississippi, Missouri, Montana, Nebraska, North Dakota, Ohio, South Dakota, Vermont, and Wyoming).
• No influenza activity was reported by one state (West Virginia).

--------------------------------------------------------------------------------

A description of surveillance methods is available at: http://www.cy118119.com/flu/weekly/fluactivity.htm

• Page last updated May 22, 2009.